How to treat VAP due to MDR pathogens in ICU patients

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Garnacho Montero, José ^a   Corcia Palomo, Yael ^a   Amaya Villar, Rosario ^a   Martin Villen, Luis ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; FOSFOMYCIN; LINEZOLID; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GRAM NEGATIVE INFECTION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MEDICAL NEBULIZER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; CROSS INFECTION; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; INTENSIVE CARE; MICROBIOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED;

ANTI-BACTERIAL AGENTS; CRITICAL CARE; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84964315756     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-135     Document Type: Review

References (68)

1. Bercault N, Boulain T: Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001, 29:2303-2309.
2. Vallés J, Pobo A, García-Esquirol O, Mariscal D, Real J, Fernández R: Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset. Intensive Care Med 2007, 33:1363-1368.
3. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombert MC, Gibert C: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998, 157:531-539.
4. Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
5. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, Garcia-Curiel A, Jiménez-Jiménez FJ: Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005, 31:649-655.
6. Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Minopoulos GI, Zakynthinos S, Manolas KI: Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 2005, 31:1488-1494.
7. Martin-Loeches I, Deja M, Koulenti D, Dimopoulos G, Marsh B, Torres A, Niederman MS, Rello J, EU-VAP Study Investigators: Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 2013, 39:672-681.
8. Koulenti D, Lisboa T, Brun-Buisson C, Krueger W, Macor A, Sole-Violan J, Diaz E, Topeli A, DeWaele J, Carneiro A, Martin-Loeches I, Armaganidis A, Rello J, EU-VAP/CAP Study Group: Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med 2009, 37:2360-2368.
9. Canadian Critical Care Trials Group: A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006, 355:2619-2630.
10. Chastre J: Conference summary: ventilator-associated pneumonia. Respir Care 2005, 50:975-983.
11. American Thoracic Society: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
12. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA: Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011, 55:4943-4960.
13. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I: Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008, 36:1089-1096.
14. Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, Cirillo I, Kimko H, Redman R: A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012, 16(6):R218.
15. Luyt CE, Aubry A, Lu Q, Micaelo M, Bréchot N, Brossier F, Brisson H, Rouby JJ, Trouillet JL, Combes A, Jarlier V, Chastre J: Imipenem, meropenem or doripenem to treat patients with pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 2014, 58:1372-1380.
16. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150.
17. Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML: Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006, 40:219-223.
18. Bulik CC, Nicolau DP: Double-carbapenem therapy for carbapenemaseproducing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011, 55:3002-3004.
19. Ceccarelli G, Falcone M, Giordano A, Mezzatesta ML, Caio C, Stefani S, Venditti M: Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013, 57:2900-2901.
20. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K: Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005, 25:11-25.
21. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME: Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010, 16:1230-1236.
22. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M: Steady-state pharmacokinetics and bronchoalveolar lavage concentration of colistin in critically ill patients after intravenous colistin methanesulfonate administration. Chest 2010, 138:1333-1339.
23. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H: Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with Gram-negative bacterial infections. Antimicrob Agents Chemother 2009, 53:3430-3436.
24. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N: High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012, 54:1720-1726.
25. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE: Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012, 56:4241-4249.
26. Pachón-Ibañez, Doboco F, Gutiérrez-Valencia A, Puppo-Moreno A, Gutiérrez-Pizarraya A, Ruiz-Valderas R, Fernández-Hinojosa E, Milara C, Leal-Noval SR, Moreno-Martínez P, Amaya R, Rosso C, López-Cortes L, Cisneros JM, Garnacho-Montero J: Pharmacokinetics of colistin after the administration of a loading dose of 4.5 mu of colistin methanesulfonate (CMS) in obese critically ill patients versus regular weight critically ill patients. Intensive care Med 2013, 39(suppl 2):S433.
27. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999, 28:1008-1111.
28. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J: Treatment of multidrug-resistant Acinetobacter baumannii ventilatorassociated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003, 36:1111-1118.
29. Reina R, Estenssoro E, Sáenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Das Neves A, Santander O, Ramos C: Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005, 31:1058-1065.
30. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, Hamida CB, Chaari A, Rekik N, Bouaziz M: Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007, 33:1162-1167.
31. http://clinicaltrials.gov/ct2/show/NCT01292031?term=colistin+and+VAP&rank=2. Accessed 20 March 2014.
32. Kollef MH: An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia. Clin Infect Dis 2003, 36:1119-1121.
33. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, Pichardo C, Jiménez L, Pachón J: Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54:1165-1172.
34. Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, Lewis R, Ferranti S, Rossolini GM, Menichetti F: Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013, 57:3990-3993.
35. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R: Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013, 57:349-358.
36. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, Kokturk F, Ornek T, Celebi G: Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013, 141:1214-1222.
37. Gordon NC, Png K, Wareham DW: Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54:5316-5322.
38. Wareham DW, Gordon NC, Hornsey M: In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011, 66:1047-1051.
39. Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, Espejo-Gutiérrez de Tena E, Artero-González ML, Corcia-Palomo Y, Bautista-Paloma J: Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant A baumannii Chemotherapy 2013, 59:225-231.
40. Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, Inkaya AC, De Pascale G, Grilli E, Tumbarello M, Akova M: Colistin-glycopeptide combination in critically ill patients with Gram negative infection: the clinical experience. Antimicrob Agents Chemother 2014, 58:851-858.
41. Arroyo LA, Mateos I, González V, Aznar J: In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi-and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009, 53:1295-1296.
42. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H, 311 Study Group: Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010, 68:140-151.
43. Curcio D, Fernández F, Vergara J, Vazquez W, Luna CM: Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009, 21:58-62.
44. Conde-Estévez D, Grau S, Horcajada JP, Luque S: Off-label prescription of tigecycline: clinical and microbiological characteristics and outcomes. Int J Antimicrob Agents 2010, 36:471-472.
45. Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, Chang SC: Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 2014, 14:102.
46. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T: Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009, 34:101-102.
47. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC: Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospitalacquired pneumonia. Antimicrob Agents Chemother 2013, 57:1756-1762.
48. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE: Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010, 10:43-50.
49. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H: Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemaseproducing Gram-negative bacteria. Int J Antimicrob Agents 2014, 43:52-59.
50. Choi EY, Huh JW, Lim CM, Koh Y, Kim SH, Choi SH, Kim YS, Kim MN, Hong SB: Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 2011, 37:639-647.
51. Haque NZ, Zuniga LC, Peyrani P, Reyes K, Lamerato L, Moore CL, Patel S, Allen M, Peterson E, Wiemken T, Cano E, Mangino JE, Kett DH, Ramirez JA, Zervos MJ: Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospitalacquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010, 138:1356-1362.
52. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC: Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011, 66:2386-2392.
53. Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA: Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob Agents Chemother 2011, 55:5507-5511.
54. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
55. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942.
56. Mimoz O, Rolland D, Adoun M, Marchand S, Breilh D, Brumpt I, Debaene B, Couet W: Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med 2006, 32:775-779.
57. Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B: Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005, 33:1529-1533.
58. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004, 30:388-394.
59. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J: Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629.
60. Palmer LB: Aerosolized antibiotics in critically ill ventilated patients. Curr Opin Crit Care 2009, 15:413-418.
61. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME: Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008, 102:407-412.
62. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G: Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010, 51:1238-1244.
63. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V: Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010, 65:2645-2649.
64. Hallal A, Cohn SM, Namias N, Habib F, Baracco G, Manning RJ, Crookes B, Schulman CI: Aerosolized tobramycin in the treatment of ventilatorassociated pneumonia: a pilot study. Surg Infect (Larchmt). 2007, 8:73-82.
65. Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS: BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012, 38:263-271.
66. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
67. Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK: Short-vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013, 144:1759-1767.
68. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M: Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34:1364-1375.